{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAP&page=11", "query": { "intervention": "TAP", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 380, "total_pages": 38, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAP&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAP&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T21:27:05.278Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02574858", "title": "Study of the Safety of QRH-882260 Heptapeptide", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adults" ], "interventions": [ { "name": "QRH-882260", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "25 Years to 100 Years" }, "enrollment_count": 25, "start_date": "2015-11", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2018-01-02", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02574858" }, { "nct_id": "NCT07288008", "title": "Transcranial Alternating Current Stimulation (tACS) for the Treatment of Anxiety in Veterans: An Open-Label Pilot Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anxiety" ], "interventions": [ { "name": "Transcranial alternating current stimulator", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Birmingham VA Health Care System", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2025-12-15", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT07288008" }, { "nct_id": "NCT00932152", "title": "Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Postmenopausal Women" ], "interventions": [ { "name": "fulvestrant (Faslodex)", "type": "DRUG" }, { "name": "anastrozole (Arimidex)", "type": "DRUG" }, { "name": "Bevacizumab (Avastin)", "type": "DRUG" }, { "name": "Best supportive care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3, "start_date": "2010-09", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2017-10-19", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00932152" }, { "nct_id": "NCT06317662", "title": "Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Asparaginase Erwinia chrysanthemi", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Calaspargase Pegol", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Prednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" }, { "name": "Thioguanine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "365 Days", "sex": "ALL", "summary": "Up to 365 Days" }, "enrollment_count": 153, "start_date": "2025-06-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 116, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06317662" }, { "nct_id": "NCT04195776", "title": "Evaluating Distribution of a Tenofovir Douche With Tap Water Douching and Simulated Receptive Anal Intercourse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV/AIDS", "HIV Prevention" ], "interventions": [ { "name": "Tenofovir Douche", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 6, "start_date": "2021-06-01", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04195776" }, { "nct_id": "NCT05278013", "title": "Utility of 2- Octyl Cyanoacrylate (2-OCA)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Ascites", "Fluid Loss" ], "interventions": [ { "name": "Dermabond", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Methodist Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 134, "start_date": "2022-01-13", "completion_date": "2024-01-13", "has_results": false, "last_update_posted_date": "2023-07-10", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05278013" }, { "nct_id": "NCT05995678", "title": "A Mixed Methods Pilot Trial of the STEP Home Workshop to Improve Reintegration and Reduce Suicide Risk for Recently Transitioned Veterans", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "TBI", "Suicide Prevention", "Veterans", "PTSD", "Transdiagnostic", "Anger" ], "interventions": [ { "name": "STEP-Home-SP", "type": "BEHAVIORAL" }, { "name": "Transition Assistance Program", "type": "BEHAVIORAL" }, { "name": "VA Solid Start", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 120, "start_date": "2024-03-01", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-03-06", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05995678" }, { "nct_id": "NCT01382238", "title": "Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Human Immunodeficiency Virus and Herpesviridae" ], "interventions": [ { "name": "Dolutegravir 50 mg tablet", "type": "DRUG" }, { "name": "Dolutegravir 50 mg oral granules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2011-06", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2011-09-19", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01382238" }, { "nct_id": "NCT04112199", "title": "A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ascites", "Decompensated Cirrhosis" ], "interventions": [ { "name": "BIV201 continuous infusion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioVie Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 15, "start_date": "2021-06-17", "completion_date": "2023-05-08", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 10, "location_summary": "Los Angeles, California • Jacksonville, Florida • Miami, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04112199" }, { "nct_id": "NCT04440475", "title": "Tap Block vs Conventional Pain Medication for Patients Undergoing Robotic Sacrocolpopexy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anesthesia, Local", "Prolapse", "Prolapse; Female", "Prolapse, Vaginal", "Prolapse; Vagina, Posthysterectomy", "Pain, Postoperative" ], "interventions": [ { "name": "TAP block", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "ProMedica Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 40, "start_date": "2020-06-28", "completion_date": "2022-01-30", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-28T21:27:05.278Z", "location_count": 1, "location_summary": "Toledo, Ohio", "locations": [ { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04440475" } ] }